In the last trading session, 1.1 million Intellia Therapeutics Inc (NASDAQ:NTLA) shares changed hands as the company’s beta touched 1.76. With the company’s per share price at $20.55 changed hands at -$0.45 or -2.14% during last session, the market valuation stood at $2.09B. NTLA’s last price was a discount, traded about -69.68% off its 52-week high of $34.87. The share price had its 52-week low at $19.21, which suggests the last value was 6.52% up since then. When we look at Intellia Therapeutics Inc’s average trading volume, we note the 10-day average is 1.55 million shares, with the 3-month average coming to 1.45 million.

Analysts gave the Intellia Therapeutics Inc (NTLA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 0 out of 13 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended NTLA as a Hold, 13 felt it is a Buy and 0 rated the stock as Underweight. Intellia Therapeutics Inc’s EPS for the current quarter is expected to be -1.39.

Intellia Therapeutics Inc (NASDAQ:NTLA) trade information

Instantly NTLA was in red as seen at the end of in last trading. With action -4.24%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -32.60%, with the 5-day performance at -4.24% in the red. However, in the 30-day time frame, Intellia Therapeutics Inc (NASDAQ:NTLA) is -10.65% down. Looking at the short shares, we see there were 14.76 million shares sold at short interest cover period of 12.37 days.

The consensus price target for the stock as assigned by Wall Street analysts is 109, meaning bulls need an upside of 81.15% from its current market value. According to analyst projections, NTLA’s forecast low is 24 with 252 as the target high. To hit the forecast high, the stock’s price needs a -1126.28% plunge from its current level, while the stock would need to soar -16.79% for it to hit the projected low.

Intellia Therapeutics Inc (NTLA) estimates and forecasts

Data shows that the Intellia Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -24.50% over the past 6 months, a -0.74% in annual growth rate that is considerably lower than the industry average of 17.70%. Year-over-year growth is forecast to reach 48.50% up from the last financial year.

Consensus estimates given by 21 financial analysts project the company’s revenue in the current quarter to hit an average of 7.86M. 21 analysts are of the opinion that Intellia Therapeutics Inc’s revenue for the current quarter will be 8.63M. The estimates for the next quarter sales put growth at -550.20%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -22.30%. The 2024 estimates are for Intellia Therapeutics Inc earnings to increase by 0.68%, but the outlook for the next 5-year period is at 30.00% per year.

NTLA Dividends

Intellia Therapeutics Inc is expected to release its next quarterly earnings report in November.

Intellia Therapeutics Inc (NASDAQ:NTLA)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 1.21% of Intellia Therapeutics Inc shares while 87.87% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 88.94%. There are 87.87% institutions holding the Intellia Therapeutics Inc stock share, with ARK INVESTMENT MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 12.1419% of the shares, roughly 11.6 million NTLA shares worth $259.51 million.

BLACKROCK INC. holds the second largest percentage of outstanding shares, with 10.0496% or 9.6 million shares worth $214.79 million as of 2024-06-30.